Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection

被引:0
|
作者
Klim, Sebastian M. [1 ]
Prattes, Juergen [2 ]
Amerstorfer, Florian [1 ]
Niedrist, Tobias [3 ]
Zurl, Christoph [2 ]
Stradner, Martin [4 ]
Dreo, Barbara [4 ]
Glehr, Gunther [5 ]
Leithner, Andreas [1 ]
Glehr, Mathias [1 ]
Reinbacher, Patrick [1 ]
Sadoghi, Patrick [1 ]
Hauer, Georg [1 ]
机构
[1] Med Univ Graz, Dept Orthopaed & Trauma, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Internal Med, Div Infect Dis, A-8036 Graz, Austria
[3] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria
[4] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, A-8036 Graz, Austria
[5] Univ Hosp Regensburg, Dept Surg, D-93053 Regensburg, Germany
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 02期
关键词
suPAR; joint infection; synovia; inflammation; diagnostic biomarker; PLASMA; INFLAMMATION; ARTHRITIS; BIOMARKER; SEPSIS; LEVEL;
D O I
10.3390/antibiotics13020179
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Soluble urokinase plasminogen activator receptors (suPARs) are a biomarker for inflammatory diseases. This study aims to investigate its diagnostic properties regarding periprosthetic joint infections (PJI). This retrospective cohort study included adult patients who underwent joint puncture for suspected PJI. The presence of PJI was determined according to the criteria of the European Bone and Joint Infection Society (EBJIS). Laboratory study analyses included the determination of white blood cells (WBC) in whole blood, C-reactive protein (CRP) in blood plasma, and suPAR in both blood plasma and synovial fluid. Appropriate diagnostic cut-off values were identified utilizing Youden's J, and their diagnostic performance was determined by calculating the positive (PPV) and negative predictive value (NPV) for each marker. Sixty-seven cases were included in the final analysis. Forty-three samples (64%) were identified as periprosthetic joint infection (PJI) and twenty-four specimen (36%) were PJI negative cases. The PPV and NPV were 0.80 and 0.70 for synovial suPAR, 0.86 and 0.55 for CRP, 0.84 and 0.31 for WBC and 1.00 and 0.31 for plasma suPAR. Synovial suPAR showed a solid diagnostic performance in this study and has the potential to be an alternative or complementary biomarker for PJI. Further investigations in larger patient collectives are indicated.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments
    Morten Alstrup
    Jeppe Meyer
    Martin Schultz
    Line Jee Hartmann Rasmussen
    Lars Simon Rasmussen
    Lars Køber
    Jakob Lundager Forberg
    Jesper Eugen-Olsen
    Kasper Iversen
    World Journal of Surgery, 2019, 43 : 780 - 790
  • [42] Soluble urokinase-type plasminogen activator receptor (SuPAR) in patients with Parkinson's disease
    Witek, N.
    Joyce, J.
    Hawkins, J.
    Liu, Y.
    Ouyang, B.
    Patel, R.
    Borgia, J.
    Reiser, J.
    Hall, D.
    MOVEMENT DISORDERS, 2021, 36 : S460 - S460
  • [43] Soluble urokinase plasminogen activator receptor (SuPAR) in patients with plasma cell dyscrasias, a pilot study
    Sudhini, Yashwanth
    Dhakal, Binod
    Reiser, Jochen
    Altintas, Mehmet
    Hahm, Eunsil
    Peev, Vasil
    Venugopal, Parameswaran
    Paner, Agne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S283 - S284
  • [44] Soluble urokinase-type plasminogen activator receptor (suPAR) - a possible biomarker for bacteremia in sepsis
    Georgescu, Anca-Meda
    Szederjesi, Janos
    Voidazan, Septimiu
    Dobreanu, Minodora
    Copotoiu, Sanda Maria
    Hutanu, Adina
    Azamfirei, Leonard
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2015, 23 (01): : 59 - 73
  • [45] Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments
    Alstrup, Morten
    Meyer, Jeppe
    Schultz, Martin
    Rasmussen, Line Jee Hartmann
    Rasmussen, Lars Simon
    Kober, Lars
    Forberg, Jakob Lundager
    Eugen-Olsen, Jesper
    Iversen, Kasper
    WORLD JOURNAL OF SURGERY, 2019, 43 (03) : 780 - 790
  • [46] Soluble urokinase activator receptor (suPAR) in stem cell mobilization
    Sloand, EM
    BLOOD, 2005, 105 (05) : 1847 - 1848
  • [47] Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
    Lee, Jiwon M.
    Yang, Jae Won
    Kronbichler, Andreas
    Eisenhut, Michael
    Kim, Gaeun
    Lee, Keum Hwa
    Shin, Jae Il
    JOURNAL OF IMMUNOLOGY RESEARCH, 2019, 2019
  • [48] Transmission of Glomerular Permeability Factor Soluble Urokinase Plasminogen Activator Receptor (suPAR) From a Mother to Child
    Kemper, Markus J.
    Wei, Changli
    Reiser, Jochen
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 61 (02) : 352 - 352
  • [49] Soluble urokinase plasminogen activator receptor (suPAR) is an independent risk factor for stroke in patients with atrial fibrillation
    Westin, O.
    Rasmussen, L. J. H.
    Andersen, O.
    Eugen-Olsen, J.
    Friberg, J.
    EUROPEAN HEART JOURNAL, 2018, 39 : 406 - 406
  • [50] Increased Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in Plasma of Suicide Attempters
    Ventorp, Filip
    Gustafsson, Anna
    Traskman-Bendz, Lil
    Westrin, Asa
    Ljunggren, Lennart
    PLOS ONE, 2015, 10 (10):